Amyloidosis: S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary
What are the good and bad effects of the study drug called isatuximab?
Basic Study Information
Purpose:Location: Cancer Center
All participants will receive the same study drug. If you decide to participate, you
will receive up to 24 cycles (1 cycles = 28 days) of the study drug, isatuximab, as
an outpatient (meaning you will not be admitted to the hospital to receive study drug.
During the first cycle (or 28 days), you will receive isatuximab on Day 1, 8, 15 and
22 by intravenous (IV) infusion (into your vein). For all other cycles (Cycle 2, up
to Cycle 24), you will receive isatuximab on Days 1 and 15.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03499808?term=A+PHASE+II+STUDY+OF+ISATUXIMAB+%28SAR650984%29+%28NSC795145%29&rank=1
Study Reference #: CMMY18034
Lead Researcher (Principal Investigator)
Lead Researcher: Frank Passero
Study Contact InformationStudy Coordinator: Andrew Bui
Phone: (585) 276-4405
Additional Study Details
Learn More About These Conditions
More information about Amyloidosis
Trial Not Found
The study you are looking for is not active at this time.
Return to Search